Daratumumab is a human IgGκ monoclonal antibody targeting CD38 with a direct on-tumor [1–4] and immunomodulatory [5–7] mechanism of action, demonstrating greater cytotoxicity toward multiple myeloma (MM) cells ex vivo compared with analogs of other CD38 antibodies [8]. Here, CD38 is linked to plasma cell myeloma.